Inpharma 1489 - 28 May 2005 Diabetes prevention another reason to value valsartan New results from the VALUE * study indicate that, in addition to its ability to reduce BP and cardiovascular risk, valsartan may also prevent diabetes mellitus in patients with hypertension. This multinational study compared the effects of valsartan and amlodipine in 15 313 patients with hypertension, 9995 of whom did not have diabetes at baseline. Data presented at the 20th Annual Scientific Meeting of the American Society of Hypertension in San Francisco, California, US, showed that patients treated with valsartan were significantly less likely to develop diabetes than those given amlodipine. After ≥ 4 years’ follow-up, 11.5% of valsartan recipients had developed diabetes, compared with 14.5% of amlodipine recipients, giving a 23% reduction in risk. Valsartan provided the greatest benefit in patients with multiple risk factors for diabetes. High blood sugar levels, faster heart rate, higher body mass index, concomitant β-blocker or diuretic therapy, younger age and non-Caucasian ethnicity were associated with an increased risk of diabetes. * Valsartan Antihypertensive Long-term Use Evaluation. See Inpharma 1443: 13, 26 Jun 2004; 800969729 University of Michigan Health System. Blood Pressure Drug Cuts Risk of Diabetes, Especially in High-Risk Individuals. Media Release : 17 May 2005. Available from: URL: http://www.med.umich.edu 809049564 1 Inpharma 28 May 2005 No. 1489 1173-8324/10/1489-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Diabetes prevention another reason to value valsartan

Download PDF Report

View
214
Download
2

Embed Size (px)

Citation preview

Inpharma 1489 - 28 May 2005

Diabetes prevention anotherreason to value valsartan

New results from the VALUE* study indicate that, inaddition to its ability to reduce BP and cardiovascularrisk, valsartan may also prevent diabetes mellitus inpatients with hypertension.

This multinational study compared the effects ofvalsartan and amlodipine in 15 313 patients withhypertension, 9995 of whom did not have diabetes atbaseline. Data presented at the 20th Annual ScientificMeeting of the American Society of Hypertension in SanFrancisco, California, US, showed that patients treatedwith valsartan were significantly less likely to developdiabetes than those given amlodipine. After ≥ 4 years’follow-up, 11.5% of valsartan recipients had developeddiabetes, compared with 14.5% of amlodipinerecipients, giving a 23% reduction in risk.

Valsartan provided the greatest benefit in patientswith multiple risk factors for diabetes. High blood sugarlevels, faster heart rate, higher body mass index,concomitant β-blocker or diuretic therapy, younger ageand non-Caucasian ethnicity were associated with anincreased risk of diabetes.* Valsartan Antihypertensive Long-term Use Evaluation. See Inpharma1443: 13, 26 Jun 2004; 800969729

University of Michigan Health System. Blood Pressure Drug Cuts Risk ofDiabetes, Especially in High-Risk Individuals. Media Release : 17 May 2005.Available from: URL: http://www.med.umich.edu 809049564